Abstract | BACKGROUND: METHODS: RESULTS: Significant reduction in triglyceride serum level was evident only among patients allocated to bezafibrate, ranging between 0.06 mmol/l (5 mg/dl) in the lowest decile of baseline triglycerides level and 0.68 mmol/l (60 mg/dl) in the highest baseline decile. The extent of triglyceride reduction with bezafibrate was significantly associated with the reduction of risk; relative risk reduction of 55% (hazards ratio: 0.45; 95% confidence interval: 0.24-0.84) was observed among patients with baseline triglycerides>or=2.26 mmol/l who reduced triglyceride level to >0.50 mmol/l (>44.3 mg/dl). In contrast, the risk of recurrent events among patients treated with bezafibrate and achieving less triglyceride reduction or failing to reduce triglyceride level was not significantly different from that of patients treated with placebo. CONCLUSION:
|
Authors | Moti Haim, Michal Benderly, Valentina Boyko, Ilan Goldenberg, David Tanne, Alex Battler, Uri Goldbourt, Solomon Behar, Bezafibrate Infarction Prevention (BIP) Study Group |
Journal | Coronary artery disease
(Coron Artery Dis)
Vol. 17
Issue 5
Pg. 455-61
(Aug 2006)
ISSN: 0954-6928 [Print] England |
PMID | 16845254
(Publication Type: Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Hypolipidemic Agents
- Triglycerides
- Clofibric Acid
- Bezafibrate
|
Topics |
- Aged
- Bezafibrate
(pharmacology, therapeutic use)
- Clofibric Acid
(pharmacology, therapeutic use)
- Female
- Humans
- Hypertriglyceridemia
(drug therapy)
- Hypolipidemic Agents
(pharmacology, therapeutic use)
- Male
- Middle Aged
- Prospective Studies
- Risk Assessment
- Risk Factors
- Secondary Prevention
- Triglycerides
(blood)
|